"The big question is whether InMode will remain in Israel," says company founder and CEO Moshe Mizrahy, talking to "Globes". The background is a control battle over the Israeli aesthetic medicine ...

The offer represents a 29% premium over InMode's closing share price last Friday, before speculation around a potential ...

Steel Partners proposes a $18 per share offer for a majority stake in InMode, citing weak returns, excess cash, and repeated ...

The company went public in 2019 at a post-money valuation of $480 million, according to the report. ・InMode has been facing ...

InMode’s products are part of the medical aesthetics industry that is expected to grow at an 11% CAGR over the next five years. Despite a punishing macro environment of late that has seen its share ...

*Please refer to "Use of Non-GAAP Financial Measures" below for important information about non-GAAP financial measures. A reconciliation between U.S. GAAP and non-GAAP Statement of Income is provided ...

Good day, and welcome to the InMode fourth quarter and full year 2024 earnings results conference call. [Operator instructions] Please note, this event is being recorded. I would now like to turn the ...

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable ...

YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results ...

Good day, and welcome to InMode's second quarter 2024 earnings results conference call. All participants will be in listen-only mode. [Operator instructions]. After today's presentation, there will be ...